Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
12 nov. 2024 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
06 nov. 2024 16h05 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
29 oct. 2024 07h46 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
11 sept. 2024 16h05 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
04 sept. 2024 07h00 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
14 août 2024 17h21 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
02 juil. 2024 16h05 HE
|
Eledon Pharmaceuticals, Inc.
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
03 juin 2024 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
09 mai 2024 07h30 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
09 mai 2024 07h00 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at ATC 2024